Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
Pediatric Blood & Cancer
|
May 16, 2024
Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Gian Luca Forni, Antonis Kattamis, Kevin H M Kuo, et al.
American Journal of Hematology
|
May 31, 2013
Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease
Weili Bao, Hui Zhong, Deepa Manwani, et al.
Blood Advances
|
June 4, 2026
Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias
Sujit Sheth, Ashutosh Lal, Abena Appiah-Kubi, et al.
Expert Review of Hematology
|
January 26, 2012
Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report
Sujit Sheth, Gerald Soff, Beau Mitchell, et al.
Hemasphere
|
July 14, 2025
Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare?
Khaled M Musallam, Sujit Sheth, Maria Domenica Cappellini, et al.
JAMA Health Forum
|
March 7, 2025
Newborn Screening for Sickle Cell Disease and Thalassemia
Maa-Ohui Quarmyne, Fiona Bock, Sangeetha Lakshmanan, et al.
Hemasphere
|
November 21, 2022
Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
Khaled M Musallam, Ali T Taher, Maria Domenica Cappellini, et al.
Blood Reviews
|
January 5, 2024
Αlpha-thalassemia: A practical overview
Khaled M Musallam, M Domenica Cappellini, Thomas D Coates, et al.
American Journal of Hematology
|
January 31, 2025
Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words
Khaled M Musallam, Sujit Sheth, Thomas D Coates, et al.
British Journal of Haematology
|
December 21, 2021
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study
Sherif M Badawy, Antonis Kattamis, Hatoon Ezzat, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
Pediatric Blood & Cancer
|
May 16, 2024
Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Gian Luca Forni, Antonis Kattamis, Kevin H M Kuo, et al.
American Journal of Hematology
|
May 31, 2013
Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease
Weili Bao, Hui Zhong, Deepa Manwani, et al.
Blood Advances
|
June 4, 2026
Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias
Sujit Sheth, Ashutosh Lal, Abena Appiah-Kubi, et al.
Expert Review of Hematology
|
January 26, 2012
Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report
Sujit Sheth, Gerald Soff, Beau Mitchell, et al.
Hemasphere
|
July 14, 2025
Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare?
Khaled M Musallam, Sujit Sheth, Maria Domenica Cappellini, et al.
JAMA Health Forum
|
March 7, 2025
Newborn Screening for Sickle Cell Disease and Thalassemia
Maa-Ohui Quarmyne, Fiona Bock, Sangeetha Lakshmanan, et al.
Hemasphere
|
November 21, 2022
Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
Khaled M Musallam, Ali T Taher, Maria Domenica Cappellini, et al.
Blood Reviews
|
January 5, 2024
Αlpha-thalassemia: A practical overview
Khaled M Musallam, M Domenica Cappellini, Thomas D Coates, et al.
American Journal of Hematology
|
January 31, 2025
Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words
Khaled M Musallam, Sujit Sheth, Thomas D Coates, et al.
British Journal of Haematology
|
December 21, 2021
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study
Sherif M Badawy, Antonis Kattamis, Hatoon Ezzat, et al.
Page
of 7